CA
NZ
UK
AU
IND
US
Insmed Inc. (NASDAQ: INSM) posted earnings per share of $-0.76 for the quarter ended March 31, 2026, comfortably beating the consensus estimate of $-0.98. The beat sparked a modest 1.2% rise in the stock, lifting the price to $109.58 in the latest session. Despite …
Niki BioSolutions completed its merger with DiamiR on July 20, 2026, converting existing equity into a unified capital structure. The deal provided 814,375 newly issued common shares and 179,693 Series A preferred shares to former Aptomer investors, while DiamiR shareholders were allocated 1,979,216 common …
MapLight Therapeutics recently submitted a Form 4 that details insider share transactions, a disclosure that can shape market perception of the company and its peers. The filing indicates that executives or directors have either increased or decreased their holdings, an event that investors closely …
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has completed an equity sale, exchanging approximately $23 million in 2028 notes for common stock and cash. The exchange has removed the 2028 notes, providing Xeris Biopharma Holdings, Inc. with more flexibility for future growth.
Eli Lilly’s $3.8 billion acquisition of psychedelic drug maker Atai has delivered a decisive buy signal to the mental health sector, positioning psychedelics as a mainstream therapeutic frontier. The deal, one of the largest in the space, underscores Big Pharma’s pivot toward once-marginalized compounds …
Vaxart Inc. (OTC: VXRT) shareholders have cast votes on several important items, notably the selection of directors and the approval of executive compensation arrangements. According to the filing, proxies representing approximately 45.7% of outstanding shares were submitted. This level of participation underscores the relevance …
NKGen Biotech has completed an amendment to its loan agreement, reinforcing its financial foundation to support ongoing and future initiatives. This adjustment reflects the company’s efforts to optimize its capital structure while maintaining operational flexibility in a competitive biotech environment. The revised terms provide …
Northwest Biotherapeutics has firmly rejected claims that UK regulators rejected its application for DCVax-L, an investigational therapy for glioblastoma. Following this clarification, the stock showed brief volatility before returning to levels near recent lows.
Novartis (Basel) stands at a key moment as three key drug studies approach their readouts later this year. The programs, one targeting a cardiovascular condition, another addressing multiple sclerosis, and a third focused on a rare genetic disorder, have the collective potential to generate …
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has announced a retention program targeting its senior leadership team, including the Chief Executive Officer, as the company prepares for a series of strategic developments. The program is structured to reinforce leadership continuity during a period of anticipated catalysts …
Please wait processing your request...